After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

The Company’s expansion efforts come amid an increase in the global focus on scalable respiratory solutions, which may position the Company as a strtegic platform for public health initiatives and ...

Doudna's insights on the future of CRISPR in medicine and agriculture, including the barriers that must be overcome to pave ...